Viking Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Viking Therapeutics, Inc. (VKTX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.24 million as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-11
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.24M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.80M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.59M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.69M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $4.24M 10-K · filed 2026-02-11 | |
| 2024-12-31 | $2.80M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $6.59M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $4.69M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $3.75M 10-K · filed 2024-02-07 | |
| 2020-12-31 | $2.60M 10-K · filed 2022-02-09 | |
| 2019-12-31 | $1.63M 10-K · filed 2021-02-17 | |
| 2018-12-31 | $1.42M 10-K · filed 2020-02-26 | |
| 2017-12-31 | $1.03M 10-K · filed 2019-03-13 | $1.03M 10-K · filed 2018-03-07 |
| 2016-12-31 | $1.29M 10-K · filed 2018-03-07 | |
| 2015-12-31 | $986.53K 10-K · filed 2017-03-21 | |
| 2014-12-31 | $6.31K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |